Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 82-85

  Sanduzzi, Alessandro ^a   Bocchino, Marialuisa ^a   Atteno, Mariangela ^a   Costa, Luisa ^a   Ponticiello, Antonio ^a   Matarese, Alessandro ^a   Spanò, Angelo ^a   Bruner, Vincenzo ^a   Peluso, Rosario ^a   Aquino, Maria Maddalena ^a   Del Puente, Antonio ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Interferon gamma release assays; Latent tubercular infection; Psoriatic arthritis

Indexed keywords

ISONIAZID PLUS RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

BCG VACCINATION; CLINICAL EXAMINATION; CONFERENCE PAPER; COST BENEFIT ANALYSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INFECTION CONTROL; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MEDICAL HISTORY; PATIENT MONITORING; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBERCULIN TEST; ARTICLE; DRUG ANTAGONISM; DRUG MONITORING; IMMUNOLOGY; MASS SCREENING; METABOLISM; METHODOLOGY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATIENT SELECTION; PREDICTIVE VALUE; TIME;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; DRUG MONITORING; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864403693     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120252     Document Type: Conference Paper

References (17)

1. World Health Organization. Global tuberculosis control - surveillance, planning, financing. Geneva: World Health Organization; 2008.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
3. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-7. (Pubitemid 34441368)
4. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52:2968-74. (Pubitemid 41447075)
5. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
6. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001;96:1665-6. (Pubitemid 32455128)
7. Wallis RS. Tumor necrosis factor antagonist: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
8. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26. (Pubitemid 34429950)
9. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884-94.
10. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. (Pubitemid 36278124)
11. Barnes PF. Diagnosing latent tuberculosis infection: the 100-year upgrade. Am J Respir Crit Care Med 2001;163:807-8. (Pubitemid 32275842)
12. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21. (Pubitemid 29036497)
13. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64. (Pubitemid 38997752)
14. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163:824-8. (Pubitemid 32275850)
15. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-13.
16. Balato N, Ayala F, Gaudiello F, Monfrecola G, Cimmino G, Ponticiello A, et al. Comparison of tuberculin skin test and interferon-gamma assays in patients with moderate to severe psoriasis who are candidates for antitumour necrosis factor-alpha therapy. Br J Dermatol 2008;158:847-9. (Pubitemid 351415717)
17. Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy. Clin Exp Rheumatol 2011;29:790-4.